GlassScriptPhysician profile
Terry R Ketch
NPI 1972658060
$3,913.60
in general payments reported to CMS, 2019-2025
30 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $381 · 2021: $1,007 · 2022: $640 · 2023: $457 · 2024: $698 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $853.33 | 2019-2023 | Xarelto |
| Pfizer INC. | $711.36 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $423.48 | 2019-2025 | Camzyos, Eliquis |
| Teleflex LLC | $259.34 | 2024 | Urolift |
| Amgen INC. | $249.64 | 2020-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $149.83 | 2019-2024 | |
| Abbott Laboratories | $131.72 | 2021-2023 | Cardiomems, Mitraclip |
| Philips North America LLC | $99.78 | 2022-2025 | Ecc Solutions, Mcot, (Ck4) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $97.48 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $93.88 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.22 | 2020-2023 | Jardiance |
| Astellas Pharma US INC | $75.86 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $74.04 | 2021-2022 | |
| Vital Connect, INC | $67.81 | 2022-2024 | Vitalpatch Rtm |
| Novo Nordisk INC | $67.15 | 2023-2025 | Wegovy, Ozempic |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $64.83 | 2020-2022 | |
| Esperion Therapeutics, INC. | $58.87 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $56.07 | 2022-2023 | Uptravi, Opsumit |
| Abiomed | $54.11 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.28 | 2024-2025 | Lifevest |
| Boston Scientific Corporation | $35.73 | 2021-2025 | Watchman Flx |
| Daiichi Sankyo INC. | $25.05 | 2025 | Injectafer |
| Acist Medical Systems, INC. | $24.12 | 2023 | |
| Cvrx, INC. | $23.56 | 2023 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $21.83 | 2021 | |
| Shockwave Medical, INC | $19.58 | 2021 | |
| Recor Medical INC | $17.51 | 2025 | Paradise Ultrasound Renal Denervation System |
| Scpharmaceuticals INC. | $15.27 | 2023 | |
| Merck Sharp & Dohme LLC | $13.52 | 2022 | |
| Zoll Respicardia, INC. | $11.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Ketch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.